Ampio: Ampion reduces all-cause mortality in COVID-19 respiratory distress by nearly 80%

Ampio: Ampion reduces all-cause mortality in COVID-19 respiratory distress by nearly 80%

ENGLEWOOD -- Ampio Pharmaceuticals (NYSE American: AMPE) announced positive results in its AP-014 Phase I clinical trial utilizing inhaled Ampion in treating respiratory distress in patients as a... Read More

Wednesday April 28, 2021 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, COVID-19, Michael Macaluso

Research shows Ampion mimics anti-inflammatory effects of steroids but without adverse effects

Research shows Ampion mimics anti-inflammatory effects of steroids but without adverse effects

ENGLEWOOD -- Ampio Pharmaceuticals (NYSE American: AMPE) announced findings of pre-clinical research demonstrating Ampio's lead drug candidate, Ampion, provides some of the same anti-inflammatory... Read More

Tuesday April 20, 2021 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Dr. David Bar-Or, Michael Macaluso

Ampio study: Ampion inhibits key inflammatory pathway in COVID-19 and lupus nephritis

Ampio study: Ampion inhibits key inflammatory pathway in COVID-19 and lupus nephritis

ENGLEWOOD -- Ampio Pharmaceuticals (NYSE American: AMPE) announced results of a pre-clinical study demonstrating Ampion inhibits an important pro-inflammatory pathway in the types of immune cells... Read More

Friday April 9, 2021 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, COVID-19, lupus nephritis, Dr. David Bar-Or

Ampio Pharmaceuticals details early positive results for inhaled Ampion in COVID-19 distress

Ampio Pharmaceuticals details early positive results for inhaled Ampion in COVID-19 distress

ENGLEWOOD -- Ampio Pharmaceuticals (NYSE American: AMPE) revealed preliminary positive results in its AP-014 Phase I clinical trial utilizing inhaled Ampion in treating respiratory distress in... Read More

Wednesday March 17, 2021 0 comments Tags: Englewood, Ampio Pharmaceuticals, Inhaled Ampion, COVID-19, Michael Macaluso

Ampio adds new hospitals in trial for inhalation treatment of COVID-19

Ampio adds new hospitals in trial for inhalation treatment of COVID-19

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced the addition of two new study sites to further the expansion of its ongoing U.S. Phase I clinical trial for inhalation... Read More

Wednesday February 24, 2021 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Mike Macaluso, COVID-19

Ampio announces early positive data in Phase 1 trial of inhaled Ampion in treating COVID-19 distress

Ampio announces early positive data in Phase 1 trial of inhaled Ampion in treating COVID-19 distress

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE American: AMPE) announced early positive data from its ongoing U.S. Phase I controlled, observer-blinded clinical trial of inhaled Ampion versus... Read More

Tuesday February 2, 2021 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, COVID-19

Ampio provides update on clinical trials for Ampion treatment of COVID-19

Ampio provides update on clinical trials for Ampion treatment of COVID-19

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced an update on the launch of a new global clinical trial for intravenous treatment of COVID-19 with Ampion and provided updates... Read More

Tuesday January 5, 2021 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Michael Macaluso, COVID-19

Ampio gets FDA feedback on proposed modifications to special protocol assessment for Ampion

Ampio gets FDA feedback on proposed modifications to special protocol assessment for Ampion

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) today announced it received guidance from the U.S Food Drug Administration regarding the impact of COVID-19 on its Phase III clinical... Read More

Wednesday December 30, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, COVID-19, FDA